Driven by increased government healthcare spending and growing life expectancy, the Indonesian pharmaceutical market value will
climb from approximately $6 billion in 2016 to $9.7 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 10%.
Indonesia's pharmaceutical industry will see higher revenues due to the introduction of a new Universal Health Care Scheme.
Rises in GDP per capita will be a major driver for the increased OTC and pharmacy consumer level spending.
More significant for overseas companies will be the Government’s changing ownership restrictions on domestic firms.
New rules will allow foreign entitied to own 100% of partnerships.
Previously the maximum ownership allowed was 75%.
Sample data: January 2021 Trastuzumab. Sample MA's and pricing.
Sample data: January 2021 Insulin Glargine. Sample MA's and pricing.